Ardelyx Quarterly Balance Sheet
NASDAQ: ARDXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ardelyx financial position
As of Jun 30, 2026, Ardelyx reported total assets of $575.9 million, up 23.4% from a year earlier against total liabilities of $426.9 million. Shareholders' equity stood at $149.0 million, or 25.9% of assets. The company held $97.2 million in cash and equivalents against $251.8 million of debt, a net debt position of $154.6 million.
The current ratio (current assets divided by current liabilities) was 3.34, meaning short-term assets cover obligations due within a year. Debt-to-equity was 1.69.
Summary generated from market data by MetaCap's automated system. Methodology
Ardelyx balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 97.19M | 31.21M | 68.00M | 42.72M | 90.05M | 30.81M | 64.93M | 47.43M | 41.89M | 36.15M | 21.47M | 33.77M |
| Short-Term Investments | 184.64M | 206.87M | 196.69M | 199.99M | 148.41M | 183.14M | 185.17M | 142.97M | 144.07M | 166.43M | 162.83M | 131.31M |
| Receivables | 100.35M | 82.84M | 71.85M | 76.61M | 62.55M | 46.47M | 57.70M | 53.20M | 37.24M | 28.16M | 22.03M | 43.26M |
| Inventory | 138.99M | 128.03M | 123.11M | 129.36M | 123.26M | 105.88M | 91.18M | 85.16M | 83.43M | 78.86M | 49.49M | 47.50M |
| Total Current Assets | 441.93M | 381.87M | 382.32M | 367.99M | 351.57M | 312.69M | 356.45M | 284.10M | 263.02M | 257.94M | 246.11M | 241.22M |
| Property, Plant & Equipment | 1.78M | 2.00M | 2.18M | 2.07M | 2.14M | 1.67M | 1.50M | 1.03M | 1.02M | 1.02M | 1.01M | 1.12M |
| Total Assets | 575.89M | 504.51M | 501.60M | 486.17M | 466.77M | 410.19M | 435.75M | 367.86M | 343.49M | 342.38M | 297.58M | 289.38M |
| Accounts Payable | 38.41M | 28.20M | 19.23M | 18.39M | 21.68M | 13.72M | 16.00M | 15.82M | 10.88M | 17.28M | 11.14M | 7.74M |
| Total Current Liabilities | 132.22M | 109.57M | 88.61M | 83.39M | 81.72M | 75.84M | 77.83M | 70.50M | 62.44M | 56.90M | 50.39M | 43.53M |
| Long-Term Debt | 251.82M | 203.52M | 202.83M | 202.14M | 201.45M | 151.30M | 150.85M | 100.71M | 100.25M | 99.83M | 49.82M | 27.23M |
| Total Liabilities | 426.88M | 355.88M | 334.65M | 331.89M | 327.24M | 264.52M | 262.46M | 209.57M | 196.50M | 191.49M | 130.76M | 98.22M |
| Shareholders' Equity | 149.01M | 148.62M | 166.95M | 154.28M | 139.53M | 145.68M | 173.29M | 158.30M | 146.99M | 150.89M | 166.82M | 191.16M |
| Retained Earnings | -1.00B | -984.54M | -946.94M | -946.53M | -945.56M | -926.48M | -885.34M | -889.99M | -889.18M | -872.72M | -846.20M | -817.40M |
| Total Debt | 251.82M | 203.52M | 202.83M | 202.14M | 201.45M | 151.30M | 150.85M | 100.71M | 100.25M | 99.83M | 49.82M | 27.23M |
| Net Cash (Debt) | 30.01M | 34.56M | 61.85M | 40.57M | 37.01M | 62.65M | 99.25M | 89.69M | 85.71M | 102.74M | 134.48M | 137.85M |
| Shares Outstanding | 249.15M | 246.97M | 244.35M | 242.97M | 240.77M | 239.20M | 238.02M | 236.89M | 235.40M | 233.96M | 232.45M | 232.13M |
This table shows 12 quarterly periods of Ardelyx's balance sheet, from Q2 2026 back to Q3 2023, across 18 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow ARDX's reporting calendar. What is a balance sheet?